Topic Highlight
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2016; 22(3): 1114-1130
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1114
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer
Ramakrishnan Ayloor Seshadri, Olivier Glehen
Ramakrishnan Ayloor Seshadri, Department of Surgical Oncology, Cancer Institute (WIA), Chennai 600036, India
Olivier Glehen, Service de Chirurgie Viscérale et Endocrinienne, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, 69495 Pierre-Bénite Cedex, France
Olivier Glehen, Université Lyon 1, EMR 3738, 69921 Oullins, France
Author contributions: Seshadri RA and Glehen O contributed equally to this paper; both authors were involved in designing the study, performing the literature research, writing and approving the final manuscript.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Olivier Glehen, Professor, Chief of Service, Service de Chirurgie Viscérale et Endocrinienne, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, 69495 Pierre-Bénite Cedex, France. olivier.glehen@chu-lyon.fr
Telephone: +33-478-862371 Fax: +33-478-863343
Received: April 28, 2015
Peer-review started: May 5, 2015
First decision: August 26, 2015
Revised: September 22, 2015
Accepted: November 30, 2015
Article in press: November 30, 2015
Published online: January 21, 2016
Core Tip

Core tip: Peritoneal carcinomatosis (PC) associated with gastric cancer has a poor prognosis. Systemic chemotherapy is not very effective in this situation and therefore, regional therapies like cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) have been investigated to improve the survival of these patients. HIPEC has been used as an adjuvant after curative resection, in the treatment of established PC and in palliating intractable ascites in gastric cancer. This review looks at the current status of HIPEC in peritoneal metastasis due to gastric cancer.